Bruns Ingmar 4
4 · Zentalis Pharmaceuticals, Inc. · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Bruns Ingmar
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-02-03+16,629→ 16,629 totalExercise: $1.68Exp: 2035-02-02→ Common Stock (16,629 underlying) - Award
Common Stock
2025-02-03+16,629→ 16,629 total
Footnotes (2)
- [F1]Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
- [F2]The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.